Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis

Aug 19, 2015European journal of clinical pharmacology

Effectiveness and side effects of canagliflozin added to metformin for treating type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Canagliflozin produced an absolute reduction in glycated hemoglobin A1c (HbA1c) of -0.66% compared to placebo in patients with type 2 diabetes mellitus.

The proportion of patients achieving target HbA1c was significantly higher in the canagliflozin group, with a ratio of 1.86.
Fasting plasma glucose (FPG) reduction was greater with canagliflozin, with decreases of 1.49 mmol/L for 100 mg/day and 1.80 mmol/L for 300 mg/day.
Significant body weight loss was observed with canagliflozin, averaging 2.09% for 100 mg/day and 2.66% for 300 mg/day.
Canagliflozin improved β cell function, indicated by a 15.59% increase in HOMA2-%B.
Higher incidences of genital mycotic infection/female and pollakiuria were reported in the canagliflozin-treated groups compared to placebo.

AI simplified

PURPOSE: The aim of this study is to assess the efficacy and tolerability of canagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, added on to metformin in patients with type 2 diabetes mellitus (T2DM).

METHODS: Literatures were searched from major electronic databases, as well as the Chinese State Food and Drug Administration and clinicaltrials.gov for unpublished studies. Only randomized controlled trials (RCTs) comparing canagliflozin with placebo in combination with metformin were included. Two reviewers independently selected studies, evaluated the risk of bias, and extracted data. The included RCTs were analyzed by the software RevMan 5.3 provided by the Cochrane Collaboration.

RESULTS: Six RCTs were chosen for the meta-analysis. Compared to placebo, canagliflozin produced absolute reduction in glycated hemoglobin A1c (HbA1c) (-0.66% [-0.72%, -0.61%]). The proportion of patients who achieved target HbA1c was significantly greater in the canagliflozin-treated group (1.86 [1.69, 2.03]). Canagliflozin led to greater fasting plasma glucose (FPG) reduction of 1.49 mmol/L (100 mg/day) and 1.80 mmol/L (300 mg/day). Significant body weight loss of 2.09% (100 mg/day) and 2.66% (300 mg/day) with canagliflozin was observed. Canagliflozin was found to improve β cell function in terms of homeostasis model assessment (HOMA2-%B) (15.59% [12.84%, 18.35%]). Higher incidences of genital mycotic infection/female and pollakiuria (increased urine frequency) were noted with canagliflozin compared with placebo-controlled groups.

CONCLUSIONS: Canagliflozin is a potential option as an add-on to metformin based on its improvement in HbA1c, FPG, body weight, and β cell function, but further studies are demanded to strengthen this evidence. Common adverse events (AEs) like genital mycotic infection/female and pollakiuria were identified.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗View full text ↗

Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief